Instil Bio Q2 2023 net loss $18.7M; cash $202.9M, ITIL-306 trial start 2H 2023

Instil Bio, Inc.

2023-Q2 EPS reported -$0.58

Net loss of $18.7M ($0.14/share) vs. $59.0M loss in Q2 2022; R&D expenses down to $8.5M from $41.5M.
Cash, equivalents, restricted cash and marketable securities $202.9M as of June 30, 2023; cash runway expected beyond 2026.
ITIL-306 (CoStAR-TIL) clinical trial ITIL-306-202 anticipated to start in 2H 2023; initial data expected in 2024.
Manufacturing process improvements doubled CoStAR-TIL yield in final product from verification runs.
Restructuring and impairment charges of $1.0M in Q2 and $25.6M for six months ended June 30, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Instil Bio, Inc. reported second quarter 2023 results: net income $0.58 for the six months ended June 30, 2023, EPS $0.14 for the three months ended June 30, 2023.

Period: second quarter 2023
Net income: $0.58 for the six months ended June 30, 2023
EPS: $0.14 for the three months ended June 30, 2023
Result: reported results

Exact text from the filing

Instil Bio, Inc. (the "Company") provided a corporate update and announced its financial results for the quarter ended June 30, 2023 in the press release attached hereto as Exhibit 99.1

View on SEC.gov

Browse all earnings releases →

Instil Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001789769-23-000083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.